InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.175 0.025 (16.67%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$22 Notification regarding unquoted securities - AGN 9 Jun 2023 10:37AM $0.390 $0.175 fallen by 55.13%
$22 Cleansing Notice 9 Jun 2023 10:21AM $0.390 $0.175 fallen by 55.13%
$22 Application for quotation of securities - AGN 9 Jun 2023 10:19AM $0.390 $0.175 fallen by 55.13%
$22 Release of Restricted Securities From Escrow 5 Jun 2023 4:33PM $0.385 $0.175 fallen by 54.55%
$22 Proposed issue of securities - AGN 2 Jun 2023 9:29AM $0.425 $0.175 fallen by 58.82%
$22 Argenica Successfully Completes $4.0m Placement 2 Jun 2023 9:29AM $0.425 $0.175 fallen by 58.82%
$22 Trading Halt 31 May 2023 9:20AM $0.425 $0.175 fallen by 58.82%
$22 Final Phase1 Clinical Trial Report 15 May 2023 8:22AM $0.420 $0.175 fallen by 58.33%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2023 8:02AM $0.445 $0.175 fallen by 60.67%
$22 Latest Preclinical HIE Study Results 20 Apr 2023 8:13AM $0.460 $0.175 fallen by 61.96%
$22 Significant Non-Dilutive Funding For Preclinical HIE Studies 30 Mar 2023 9:28AM $0.420 $0.175 fallen by 58.33%
$22 Interim Phase 1 Safety Report Confirms Safety of ARG-007 6 Mar 2023 8:16AM $0.440 $0.175 fallen by 60.23%
$22 Half Yearly Report and Accounts 28 Feb 2023 7:51AM $0.430 $0.175 fallen by 59.30%
$22 Non-Dilutive Funding Received to Progress Alzheimers Studies 22 Feb 2023 8:06AM $0.445 $0.175 fallen by 60.67%
$22 Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers 9 Feb 2023 8:16AM $0.405 $0.175 fallen by 56.79%
$22 Investor Presentation 2 Feb 2023 8:19AM $0.430 $0.175 fallen by 59.30%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 7:42AM $0.435 $0.175 fallen by 59.77%
$22 Argenica Awarded $1.2m CRC-P Grant for TBI Project 20 Jan 2023 9:15AM $0.445 $0.175 fallen by 60.67%
$22 Successful Completion of Phase 1 Clinical Trial Dosing 21 Dec 2022 8:20AM $0.455 $0.175 fallen by 61.54%
$22 Ceasing to be a substantial holder 12 Dec 2022 6:00PM $0.490 $0.175 fallen by 64.29%
$22 SRC Approves Commencement Of Fourth And Final Cohort Dosing 8 Dec 2022 9:39AM $0.495 $0.175 fallen by 64.65%
$22 Change of Director's Interest Notice 30 Nov 2022 8:18AM $0.555 $0.175 fallen by 68.47%
$22 Notification regarding unquoted securities - AGN 30 Nov 2022 8:17AM $0.555 $0.175 fallen by 68.47%
$22 Phase 1 Clinical Trial Progress Update 25 Nov 2022 8:20AM $0.540 $0.175 fallen by 67.59%
$22 AGM Presentation 25 Nov 2022 8:20AM $0.540 $0.175 fallen by 67.59%

176 - 200 of 291 results

Page 8 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.